Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Oct 25;13(21):6391.
doi: 10.3390/jcm13216391.

EGFR-Targeted Therapies: A Literature Review

Calista Sha  1 , Paul C Lee  1
Affiliations
Review

EGFR-Targeted Therapies: A Literature Review

Calista Sha et al. J Clin Med. .

Abstract

Lung cancer remains the leading cause of cancer death in the United States, underscoring the critical need to optimize treatment strategies. Compared to conventional treatments such as surgical resection, radiotherapy, chemotherapy, and immunotherapy, targeted therapy stands out for its higher selectivity and minimal adverse effects. Among these, epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are the most widely used in targeted therapy for non-small-cell lung cancer (NSCLC). In our paper, we will conduct a comprehensive review of current literature on EGFR TKIs to contribute to advancements in molecular genomics and the treatment of lung cancer.

Keywords: EGFR; NSCLC; TKI; lung cancer.

PubMed Disclaimer

Conflict of interest statement

Authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Timeline of developments and major research breakthroughs of first-, second-, third- and fourth-generation EGFR TKIs.
See this image and copyright information in PMC

References

    1. Siegel R.L., Giaquinto A.N., Jemal A. Cancer statistics, 2024. CA Cancer J. Clin. 2024;74:12–49. doi: 10.3322/caac.21820. - DOI - PubMed
    1. Saller J.J., Boyle T.A. Molecular Pathology of Lung Cancer. Cold Spring Harb. Perspect. Med. 2022;12:a037812. doi: 10.1101/cshperspect.a037812. - DOI - PMC - PubMed
    1. Cheng Y., Zhang T., Xu Q. Therapeutic advances in non-small cell lung cancer: Focus on clinical development of targeted therapy and immunotherapy. MedComm. 2021;2:692–729. doi: 10.1002/mco2.105. - DOI - PMC - PubMed
    1. Forsythe M.L., Alwithenani A., Bethune D., Castonguay M., Drucker A., Flowerdew G., French D., Fris J., Greer W., Henteleff H., et al. Molecular profiling of non-small cell lung cancer. PLoS ONE. 2022;12:e0236580. doi: 10.1371/journal.pone.0236580. - DOI - PMC - PubMed
    1. Seshacharyulu P., Ponnusamy M.P., Haridas D., Jain M., Ganti A.K., Batra S.K. Targeting the EGFR signaling pathway in cancer therapy. Expert Opin. Ther. Targets. 2012;16:15–31. doi: 10.1517/14728222.2011.648617. - DOI - PMC - PubMed

LinkOut - more resources